- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00913263
An Efficacy and Safety Study With Licroca Depot, a Controlled Release Product, Injected Into the Prostate (2-HOF)
January 15, 2015 updated by: Lidds AB
An Open, Single and Multiple Dose, Efficacy and Safety Proof of Principle Study of Liproca Depot, a Controlled Release Formulation of 2-hydroxyflutamide, Injected Into the Prostate in Patients With Localized Prostate Cancer
The primary objective was to evaluate efficacy of a single dose of Liproca Depot in patients with localized prostate cancer.
Primary efficacy variable was the proportion of patients showing PSA nadir.
24 Caucasian men, with a mean age at inclusion of 68.4 years, with localized prostate cancer were injected once with a ready made paste including 600 mg 2-hydroxyflutamide (Liproca Depot) into the site of the prostate where the tumour was localized.
The patient was monitored for prostate-specific antigen (PSA) for maximum 6 months or to progression within this time period.
The primary endpoint showed interesting results with high success rate (83%), i.e. proportion of patients (Responders) that reached plasma PSA nadir.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Patients with localized prostate cancer were followed to progression or maximum 24 weeks after a single injection in one lobe of 2-8 mL ready-made paste (corresponding to 400-1600 mg 2-Hydroxyflutamid).
Progression was defined as an increase in PSA by > 25% over baseline or on-treatment nadir.Among the 24 patients the primary endpoint, plasma PSA nadir, was reached by 20 patients (Responders).
Efficacy was measured primarily as PSA nadir, and secondly as time to PSA nadir and prostate volume change.
Safety was monitored throughout the whole study period.
Study Type
Interventional
Enrollment (Actual)
24
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Tampere, Finland
- Tampere University Hospital
-
Tampere, Finland, 33520
- Tampere University Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
45 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Age ≥ 45years
- Histologically confirmed localized prostate cancer (T1-T2), predominantly in one side of the peripheral zone, verified by biopsy.
- PSA value < 20 ng/ml within 6 weeks before enrolment.
- Gleason score ≤ 3+4 at diagnostic biopsy
- Adequate renal function: Creatinine < 1.5 times upper limit of normal.
- Adequate hepatic function: ASAT, ALAT and ALP < 1.5 times upper limit of normal.
- Negative dipstick for bacturia.
- Patient must have ability to cope with the study procedures and to return to scheduled visits including follow up visit.
Exclusion Criteria:
- Previous or ongoing hormone therapy for prostate cancer.
- Ongoing or previous therapy (within3 month) of finasteride or dutasteride.
- Ongoing or previous invasive therapy for benign prostate hyperplasia (TURP, TUMT).
- Symptoms or signs of acute prostatitis.
- Symptoms or signs of ulceric proctitis
- Severe micturation symptoms (I-PSS >17)
- Concomitant systemic treatment with corticosteroids, or immunomodulating agents.
- Known immunosuppressive disease (e.g. HIV, insulin dependent diabetes).
- Simultaneous participation in any other study involving not market authorized drugs or having participated in a study within the last 12 months prior to start of study treatment.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 2-Hydroxyflutamide
Single injection of 2-Hydroxyflutamide (2-8mL ready-made paste)in one prostate lobe
|
Ready made paste including 600 mg 2-HOF for injection as a single dose
Other Names:
The Product consists of two sterile components, one aqueous liquid and a dry powder, containing the active drug 2-Hydroxyflutamide (2-HOF.
The two components were mixed under aceptic conditions to a paste prior to administration.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of Patients Showing PSA Nadir
Time Frame: Measured every 4th week until progression or maximum 6 months.
|
Plasma PSA nadir is the lowest PSA reading achieved after any treatment for prostate cancer.
The patients were observed once every 4th week during the study period.
|
Measured every 4th week until progression or maximum 6 months.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Patients Reporting Adverse Events Caused by the Study Treatment
Time Frame: Measured every 4th week till progression or maximum 6 months
|
|
Measured every 4th week till progression or maximum 6 months
|
Percent Change in Prostate Volume From Baseline to Nadir.
Time Frame: Measured every 4th week until progression or maximum 6 months.
|
Prostate volume was measured at each visit to capture nadir and compared to baseline for all patients.
Decrease in prostate volume is reported as percent change from baseline.
|
Measured every 4th week until progression or maximum 6 months.
|
Time to PSA Nadir
Time Frame: Measured every 4th week until progression or maximum 6 moths.
|
Time frame was from baseline to day of PSA nadir.
|
Measured every 4th week until progression or maximum 6 moths.
|
Percent Change in Prostate Volume From Baseline to Final Visit
Time Frame: Measured every 4th week until progresion or maximum 6 months.
|
Prostate volume was captured at each visit and percent change from baseline to final visit was measured.
Final visit was either day of progression or after 6 months.
Prostate volume decrease is reported in percent change from baseline
|
Measured every 4th week until progresion or maximum 6 months.
|
Number of Days to Prostate Volume Nadir.
Time Frame: Measured every 4th week until progression or maximum 6 months.
|
Number of Days from day of injection to prostate volume nadir.
|
Measured every 4th week until progression or maximum 6 months.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Teuvo Tammela, Professor, Tampere University Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2009
Primary Completion (Actual)
May 1, 2011
Study Completion (Actual)
July 1, 2011
Study Registration Dates
First Submitted
June 3, 2009
First Submitted That Met QC Criteria
June 3, 2009
First Posted (Estimate)
June 4, 2009
Study Record Updates
Last Update Posted (Estimate)
January 19, 2015
Last Update Submitted That Met QC Criteria
January 15, 2015
Last Verified
April 1, 2013
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Genital Neoplasms, Male
- Prostatic Diseases
- Prostatic Neoplasms
- Physiological Effects of Drugs
- Antineoplastic Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Hormone Antagonists
- Androgen Antagonists
- Flutamide
- Hydroxyflutamide
Other Study ID Numbers
- LPC-002
- 2009-010079-25 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Cancer
-
Roswell Park Cancer InstituteRecruitingObesity | Overweight | Cancer Survivor | Prostate Adenocarcinoma | Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage A Prostate Cancer | Stage... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Regeneron Pharmaceuticals; Prostate Cancer FoundationWithdrawnStage III Prostate Cancer | Stage IV Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage IIIA Prostate Cancer | Stage IIIB Prostate Cancer | Stage IIIC Prostate Cancer
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI); SanofiTerminatedDiarrhea | Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Ryan Kohlbrenner, MDRadiological Society of North AmericaCompletedProstate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Prostate Carcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage...United States
-
Jonsson Comprehensive Cancer CenterProgenics Pharmaceuticals, Inc.TerminatedRandomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer (PSMA-dRT)Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Stage I Prostate...United States
-
Ohio State University Comprehensive Cancer CenterRiverside Methodist HospitalCompletedStage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
University of California, IrvineCompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnStage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate...United States
-
NRG OncologyNational Cancer Institute (NCI)RecruitingProstate Adenocarcinoma | Stage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer... and other conditionsUnited States
Clinical Trials on 2-hydroxyflutamide (2-HOF) [Liproca Depot]
-
Lidds ABUppsala UniversityCompletedProstate CancerFinland, Sweden
-
Lidds ABCMX ResearchCompletedProstate CancerCanada, Finland, Lithuania
-
TakedaRecruitingCentral Precocious PubertyChina
-
National Cancer Institute (NCI)CompletedLung Carcinoid Tumor | Metastatic Digestive System Neuroendocrine Tumor G1 | Paraganglioma | Pancreatic Polypeptide Tumor | Pancreatic Glucagonoma | Pancreatic Insulinoma | Recurrent Merkel Cell Carcinoma | Somatostatin-Producing Neuroendocrine Tumor | Stage IV Merkel Cell Carcinoma | Recurrent Digestive... and other conditionsUnited States
-
Eli Lilly and CompanyCompletedSchizophreniaUnited States, Russian Federation, Croatia
-
Roswell Park Cancer InstituteNeuroEndocrine Tumor Research Foundation (NETRF)RecruitingLung Atypical Carcinoid Tumor | Metastatic Pancreatic Neuroendocrine Tumor | Lung Typical Carcinoid TumorUnited States
-
FHI 360University of Washington; University of North Carolina, Chapel Hill; World Health... and other collaboratorsCompletedHIV | ContraceptionKenya, South Africa, Swaziland, Zambia
-
Xijing Hospital of Digestive DiseasesUnknownGastrointestinal Imaging With pCLEChina
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingStage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostate Adenocarcinoma | Castration-Sensitive Prostate CarcinomaUnited States
-
M.D. Anderson Cancer CenterActive, not recruitingProstate Adenocarcinoma | Recurrent Prostate CarcinomaUnited States